Maria Laura Saladino
Overview
Explore the profile of Maria Laura Saladino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
746
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharmin S, Bovis F, Malpas C, Horakova D, Kubala Havrdova E, Izquierdo G, et al.
Eur J Neurol
. 2022 May;
29(8):2321-2334.
PMID: 35582938
Background And Purpose: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on...
2.
Alonso R, Quarracino C, Eizaguirre B, Cohen L, Silva B, Pita C, et al.
Neurol Sci
. 2021 Sep;
42(12):5441.
PMID: 34557969
No abstract available.
3.
Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, et al.
Neurology
. 2020 Dec;
96(5):e783-e797.
PMID: 33372028
Objective: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. Methods: We studied patients from MSBase followed for...
4.
Alonso R, Quarracino C, Eizaguirre B, Cohen L, Silva B, Pita C, et al.
Neurol Sci
. 2020 Aug;
41(11):3329-3335.
PMID: 32840711
Background: Primary progressive multiple sclerosis (PPMS) is an infrequent clinical form of multiple sclerosis (MS). Scarce information is available about PPMS in Latin America. The aim of this work is...
5.
Rojas J, Alonso Serena M, Garcea O, Patrucco L, Carra A, Correale J, et al.
Neurol Sci
. 2020 Jan;
41(6):1513-1519.
PMID: 31960250
Methods: RelevarEM is a longitudinal, strictly observational MS and NMOSD registry in Argentina. Epidemiological and comorbidity data from MS and NMOSD patients were described and compared. For comorbidities, the Charlson...
6.
Cristiano E, Rojas J, Alonso R, Pinheiro A, Bacile E, Balbuena M, et al.
J Neurol Sci
. 2019 Dec;
409:116609.
PMID: 31816524
Introduction: During the last 20 years, multiple sclerosis (MS) disease has seen major changes with new diagnostic criteria, a better identification of disease phenotypes, individualization of disease prognosis and the...
7.
Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, et al.
Mult Scler
. 2019 Aug;
26(1):79-90.
PMID: 31397221
Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of this study was to determine the demographic, clinical and paraclinical...
8.
Saposnik G, Mamdani M, Montalban X, Terzaghi M, Silva B, Saladino M, et al.
MDM Policy Pract
. 2019 Jul;
4(1):2381468319855642.
PMID: 31259250
Therapeutic inertia (TI) is a common phenomenon among physicians who care for patients with chronic conditions. We evaluated the efficacy of the traffic light system (TLS) educational intervention to reduce...
9.
Saposnik G, Mamdani M, Terzaghi M, Saladino M, Silva B, Tobler P, et al.
Front Neurol
. 2018 Oct;
9:835.
PMID: 30369904
The prescription of generic (non-proprietary) compared to brand-name drugs is increasing worldwide. In many developing and emerging countries, generics companies market products at similar costs as brand-name competitors benefiting from...
10.
Cristiano E, Alonso R, Pinheiro A, Bacile E, Balbuena M, Ballario C, et al.
J Neurol Sci
. 2018 Feb;
387:231-232.
PMID: 29449007
No abstract available.